Compare Heron Therapeutics Inc (HRTX) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.41 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 1788.2× Heron Therapeutics Inc's market cap, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| HRTX | VIG | |
|---|---|---|
Market Cap | $74.04M | $132.40B |
Volume | 3,668,095 | 1,733,469 |
Sector | Health | — |
52-Week High | $1.49 | $246.61 |
52-Week Low | $0.27 | $210.70 |
Typical Hold Time | 35 Days | 133 Days |
Enterprise Value | $180.78M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
VIG trades at $236.99, down 0.32% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF focuses on dividend growth companies with at least 10 consecutive years of dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights VIG's 7.5% quarterly dividend increase and its strategic positioning for long-term income investors.
VIG presents a compelling option for investors seeking dividend growth with moderate risk, though its low current yield may not suit income-focused portfolios. Key risks include market volatility and the ETF's exclusion of high-yield dividend payers. Analyst sentiment remains positive given its historical 10% annual returns and quality screening criteria.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
